Status:

RECRUITING

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Lead Sponsor:

Jacobio Pharmaceuticals Co., Ltd.

Conditions:

Advanced Solid Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This study is to evaluate the safety and tolerability of JAB-23E73 in adult participants with advanced solid tumors

Detailed Description

Study JAB-23E73-1002 is a multicenter, open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of JAB-23E73 as a singl...

Eligibility Criteria

Inclusion

  • Written informed consent.
  • Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
  • Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
  • Patients must have KRAS alterations.
  • Participants are required to provide an archived tumor sample.
  • Patients with a life expectancy ≥3 months.
  • ECOG performance status score of 0 or 1.
  • Patients must have at least one measurable lesion as defined by RECIST v1.1.

Exclusion

  • Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.
  • Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan/multi-KRAS inhibitors.
  • Known serious allergy to JAB-23E73 or excipient.
  • Patients with primary central nervous system tumors.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.
  • QT interval\>470 msec.
  • LVEF ≤50% assessed by ECHO or MUGA.

Key Trial Info

Start Date :

May 29 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2028

Estimated Enrollment :

294 Patients enrolled

Trial Details

Trial ID

NCT06973564

Start Date

May 29 2025

End Date

February 1 2028

Last Update

November 12 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

2

Washington University

St Louis, Missouri, United States, 63110

3

Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

4

Huntsman Cancer Institute

Salt Lake City, Utah, United States, 84112